SCHEMBL1268573

SCHEMBL1268573

O=Cc1ccccc1COC(=O)CCl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 5/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRIM24 O15164 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10775904 0.85 ALDH1A1 (0.36) MEN1KMT2AALDH1A1HTTPOLB
SCHEMBL1268522 0.84 ALDH1A1 (0.40) PTGDR2MEN1LMNATHRBBLM
SCHEMBL17491378 0.79 LMNA (0.41) PTGDR2MEN1LMNATHRBBLM
SCHEMBL442438 0.79 ALDH1A1 (0.52) PTGDR2MEN1LMNATHRBBLM
SCHEMBL878376 0.77 PPARG (0.58) PTGDR2LMNAKMT2ATDP1ALDH1A1
SCHEMBL292345 0.75 TP53 (0.54) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL30873521 0.75 TP53 (0.54) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL12317473 0.74 KMT2A (0.48) PTGDR2MEN1LMNATHRBBLM
SCHEMBL6801271 0.74 ALDH1A1 (0.62) PTGDR2LMNAKMT2ATDP1ALDH1A1
SCHEMBL4644461 0.74 ALDH1A1 (0.55) PTGDR2MEN1LMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2955171-A1 MANUFACTURE PROCESS OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID Novartis AG (CH) 2015-12-16 EP disclosed
EP-1838664-B1 MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES NOVARTIS AG (CH) 2015-07-15 EP disclosed
US-8461385-B2 Manufacture process of organic compounds NOVARTIS AG (CH) 2013-06-11 US disclosed
US-8314071-B2 Bioactive molecules from co-cultivation of microbes MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-11-20 US disclosed
US-8026383-B2 Process for the preparation of intermediates useful in the synthesis of statin derivatives BASF SE (DE) 2011-09-27 US disclosed
US-20110046411-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES CIBA SPECIALTY CHEMICALS CORPORATION 2011-02-24 US disclosed
US-7855302-B2 Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof CIBA SPECIALTY CHEMICALS CORP. (US) 2010-12-21 US disclosed
US-20100249051-A1 Bioactive Molecules from Co-Cultivation of Microbes MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-09-30 US disclosed
US-7692034-B2 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-04-06 US disclosed
EP-2161250-A1 Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation BASF SE (DE) 2010-03-10 EP disclosed
US-7199261-B2 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2007-04-03 US disclosed
WO-2006063821-A1 MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES NOVARTIS AG (CH) 2006-06-22 WO disclosed
US-20050033086-A1 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives BASF SE (DE) 2005-02-10 US disclosed
US-20050014954-A1 Pyrrole synthesis CIBA SPECIALTY CHEMICALS CORP. 2005-01-20 US disclosed
US-20040242916-A1 Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation BASF SE (DE) 2004-12-02 US disclosed
US-20040186313-A1 Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof CIBA SPECIALTY CHEMICALS CORP. 2004-09-23 US disclosed
EP-1451179-A1 PYRROLE SYNTHESIS Ciba SC Holding AG (CH) 2004-09-01 EP disclosed
EP-1404639-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF Ciba SC Holding AG (CH) 2004-04-07 EP disclosed
WO-2003044011-A1 PYRROLE SYNTHESIS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-05-30 WO disclosed
WO-2003004450-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046411-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES HMGCR, SREBF1, LCAT PTGDR2 4724/4885MEN1 2460/4885LMNA 1340/4885
US-20040186313-A1 Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof HMGCR, CYP46A1, CYP7A1 PTGDR2 4062/4885MEN1 3537/4885LMNA 1993/4885
US-20100249051-A1 Bioactive Molecules from Co-Cultivation of Microbes BMP4, BMP2, LSS PTGDR2 1863/4885MEN1 1638/4885LMNA 1957/4885
US-20050014954-A1 Pyrrole synthesis PNPO, PPOX, DHPS PTGDR2 255/4885MEN1 1362/4885LMNA 4840/4885
US-20050033086-A1 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives HMGCR, DHCR7, HCAR3 PTGDR2 3168/4885MEN1 2332/4885LMNA 890/4885
US-20040242916-A1 Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation HMGCR, DHCR7, CYP8B1 PTGDR2 2578/4885MEN1 1766/4885LMNA 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.